Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for separating and purifying high-purity activated clotting seventh factors from cell culture solution or plasma components

A cell culture, separation and purification technology, applied in the field of separation and purification of high-purity activated blood coagulation factor seven, can solve problems such as adverse reactions, achieve good safety, simple and efficient thrombin activation process, and improve comprehensive utilization

Inactive Publication Date: 2011-08-24
SYNDEGEN SHANGHAI BIOTECH
View PDF1 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since PCC is a mixture of several coagulation factors, it is easy to produce adverse reactions in clinical application, such as thromboembolism, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for separating and purifying high-purity activated clotting seventh factors from cell culture solution or plasma components
  • Method for separating and purifying high-purity activated clotting seventh factors from cell culture solution or plasma components
  • Method for separating and purifying high-purity activated clotting seventh factors from cell culture solution or plasma components

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] The preparation of embodiment 1 affinity chromatography medium

[0053] Affinity chromatography medium: CNBr-activated Sepharose 4Fast Flow or CNBr-activated Sepharose 4B product from GE Healthcare.

[0054] Preparation of seven-factor monoclonal antibodies:

[0055] Construct hybridoma cells according to conventional methods, and extract RNA from hybridoma cells that can produce anti-activated blood coagulation factor VII, convert RNA into single-stranded DNA in reverse transcription reaction, and then amplify with two pairs of designed primers respectively. The light chain and heavy chain variable region sequences were increased, and the obtained products were respectively cloned into pMD18-T vector. Sequence the obtained light chain and heavy chain sequences, and design the whole gene sequences of the light chain and heavy chain according to the sequencing results:

[0056] Light chain DNA sequence: (SEQ ID NO: 3)

[0057] ATGGGATGGTCCTGCATCATCCTGTTCCTGGTGGCAACTGC...

Embodiment 2

[0068] Example 2 Component II+III affinity chromatography to separate seven factors

[0069] 100ml of plasma fraction II+III sample with a protein content of 10% was added to 100ml of pH7.4 sodium dihydrogen phosphate / disodium hydrogen phosphate buffer solution to dilute evenly, and used as the sample before affinity chromatography purification. Seven-factor antibody affinity chromatography column 50ml equilibrated with pH 7.4 sodium dihydrogen phosphate / disodium hydrogen phosphate buffer solution for 5 column volumes, flow rate 5ml / min, loading 200ml of component II+III dilution, control flow rate 3ml / min, collecting 300ml of the breakthrough peak. After loading the sample, rinse with sodium dihydrogen phosphate / disodium hydrogen phosphate buffer solution to the baseline. Use pH 2.5-5.0 glycine / hydrochloric acid buffer solution to elute the seven factors (preferably pH 2.5 glycine / hydrochloric acid buffer solution to elute the seven factors), the elution flow rate is 5ml / mi...

Embodiment 3

[0072] Example 3 Separation of Seven Factors by Affinity Chromatography Using Seven Factors Cell Culture Fluid as Raw Material

[0073] Suspension culture of seven-factor cells in serum-free medium in a bioreactor, when the cell density reaches 1X10 7 Cells / ml, when the concentration of seven factors reaches 10 mg / l, collect 20 liters of supernatant samples of the culture medium, use pH 7.4 sodium dihydrogen phosphate / disodium hydrogen phosphate buffer solution for ultrafiltration and concentration to 2000 ml, and use it as affinity chromatography Samples before purification. 50ml of seven-factor antibody affinity chromatography column was equilibrated with 5 column volumes of sodium dihydrogen phosphate / disodium hydrogen phosphate buffer solution with pH 7.4, the equilibrium flow rate was 5ml / min, 2000ml of plasma sample was loaded, 2150ml of breakthrough peak was collected, and The sample flow rate is 10ml / min. After loading the sample, rinse with sodium dihydrogen phospha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for separating and purifying high-purity activated clotting seventh factors from a cell culture solution or plasma components, successively comprising the following steps: carrying out affinity chromatography purification on raw materials; collecting an eluent containing a clotting seventh factor; adding thrombin and magnesium ions to activate the clotting seventh factor; and finally, condensing an activated product, and carrying out virus inactivation to obtain a final product. The clotting seventh factor can be purified in one step with the affinity chromatography method, the thrombin activation process is simple and efficient, the seventh factor can be purified and separated from the cell culture solution or plasma components, the multipurpose utilization ratio of the plasma is greatly improved, and a safe and efficient high-purity seventh factor protein drug can be provided.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a method for separating and purifying high-purity activated blood coagulation factor seven from cell culture fluid or plasma components. Background technique [0002] Coagulation factor VII (FVII) is a vitamin K-dependent glycoprotein, synthesized in the liver, and exists in a very low concentration (0.5mg / L) in the blood, and mainly exists in the form of an inactive single-chain zymogen, only 1% are activated. Factor seven zymogens can be activated by activated coagulation factors twelfth, ten, nine, seven, or thrombin to form activated factor seven (FVIIa). Factor seven is the zymogen necessary to start the extrinsic coagulation pathway, and its activation is the beginning of the extrinsic coagulation pathway. Activated factor VII itself has very low proteolytic activity, while tissue factor (TF) is a highly affinity receptor for activated factor VII. Once activated facto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/745C07K1/22C07K1/14
Inventor 许必雄郭颀然
Owner SYNDEGEN SHANGHAI BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com